在已确认和怀疑的TDP-43型C病理中神经退行症的空间和时间进展
Jane Stocks1,2, Jordan Behn2, Elena Barbieri2,3
1Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA 60611.
Imaging neuroscience (Cambridge, Mass.)
|August 5, 2025
概括
在TDP-43蛋白质病变型C (TDP-C) 的前叶退化中神经退化开始于前叶并向后扩散. 这项研究使用未受影响的半球来追踪TDP-C的早期缩模式,帮助治疗评估.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 放射学 放射学是一门学科.
背景情况:
- 划分神经退行性疾病的进展为病理生理学提供了洞察力,并有助于治疗评估.
- 在阿尔茨海默病 (AD),FTLD-tau和FTLD-TDP类型A和B方面的进展已经利用了症状前的突变载体.
- 这种方法对于FTLD-TDP型C (TDP-C) 是不可行的,因为没有主导突变和微妙的早期症状.
研究的目的:
- 重建TDP-C.中神经退行症的空间和时间进展.
- 通过分析最初不受影响的半球来克服TDP-C中迟诊断的局限性.
- 为改善治疗评估提供有关疾病早期阶段的见解.
主要方法:
- 在因TDP-C.而导致不对称的左前缩缩症患者中,对未受影响 (右) 半球进行纵向分析.
- 结构性MRI处理使用基于voxel的形态测量和分为皮层和皮层下区域的分片.
- 计算体积损失的W-分数,并应用线性混合效应模型来评估感兴趣区域 (ROI) 的疾病进展.
主要成果:
- 在TDP-C的缩遵循一个刻板的进展,从中腹前叶开始,向后和侧向扩散.
- 早期缩在中间极,周围内皮质,内皮质和前状皮质中最为突出,最初涉及杏仁体.
- 皮质缩之前和超过杏仁体缩,表明更大的新皮质的脆弱性,最大的体积损失在中间时ROI和杏仁体沿着前后梯度.
结论:
- 最初不受影响的半球作为TDP-C早期疾病阶段的代理,揭示了神经退行症的刻板印象轨迹.
- 这种重建的进展与神经病理模式保持一致,为理解TDP-C提供了关键的见解.
- 通过澄清TDP-C进展的自然过程,研究结果有助于评估治疗干预措施.
相关概念视频
Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
Parkinson's Disease: Overview
708
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
708


